IDT Australia Limited reported sales results for the third quarter ended March 2023. For the quarter, revenue jumped 26% to $2.14 million over the previous quarter (and +168% over two quarters) due primarily to contracts won in IDT's Specialty Orals division. The demand outlook for Specialty Orals manufacturing is growing due to several factors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.095 AUD | -2.06% | 0.00% | -13.64% |
Apr. 16 | IDT Australia Signs Master Service Agreement with Sanofi | MT |
Feb. 21 | IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-13.64% | 21.78M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IDT Stock
- News IDT Australia Limited
- IDT Australia Limited Reports Sales Results for the Third Quarter Ended March 2023